797.7500 -6.65 (-0.83%)
NSE Aug 11, 2025 15:31 PM
Volume: 180.8K
 

797.75
-0.83%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading above its 150 day SMA of 724.8
More from Strides Pharma Science Ltd.
Recommended